BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38214336)

  • 1. Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design.
    Xin K; Wei X; Shao J; Chen F; Liu Q; Liu B
    Hum Vaccin Immunother; 2024 Dec; 20(1):2300881. PubMed ID: 38214336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
    Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
    Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
    Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
    J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer.
    Liu Q; Chu Y; Shao J; Qian H; Yang J; Sha H; Cen L; Tian M; Xu Q; Chen F; Yang Y; Wang W; Wang K; Yu L; Wei J; Liu B
    Adv Sci (Weinh); 2022 Nov; 10(1):e2203298. PubMed ID: 36351249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
    Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
    Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
    Chen I; Chen MY; Goedegebuure SP; Gillanders WE
    Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
    [No Abstract]   [Full Text] [Related]  

  • 10. Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land.
    Yu G; He X; Li X; Wu Y
    Biomed Pharmacother; 2022 Sep; 153():113464. PubMed ID: 36076493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy.
    Supabphol S; Li L; Goedegebuure SP; Gillanders WE
    Expert Opin Investig Drugs; 2021 May; 30(5):529-541. PubMed ID: 33641576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report.
    Shao J; Liu Q; Shen J; Qian X; Yan J; Zhu Y; Qiu X; Lu C; Cen L; Tian M; Du J; Liu B
    Front Immunol; 2022; 13():799026. PubMed ID: 35273594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.
    Wu Y; Feng L
    Expert Opin Drug Deliv; 2023 Mar; 20(3):323-333. PubMed ID: 36634017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.
    Kim S; Kim HS; Kim E; Lee MG; Shin EC; Paik S; Kim S
    Ann Oncol; 2018 Apr; 29(4):1030-1036. PubMed ID: 29360924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines.
    Kang Y; Zhang W; Yu Q; Gao L; Quan J; Gu F; Wu Y; Tian Y; Wu Z; Shao S; Zhou H; Duan S; Zhou Y; Zhang L; Gao X; Tian H; Yao W
    Cancer Immunol Immunother; 2023 Aug; 72(8):2741-2755. PubMed ID: 37119260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
    Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
    Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity.
    Wu J; Wang W; Zhang J; Zhou B; Zhao W; Su Z; Gu X; Wu J; Zhou Z; Chen S
    Front Immunol; 2019; 10():2559. PubMed ID: 31736974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.